Skip to main content

Table 2 Description of patients by treatment arm and clinical setting

From: Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

  Whole set Locally advanced Metastatic not pre-treated with anthracyclines Metastatic pre-treated with anthracyclines
  3-weekly
N = 69
Weekly
N = 66
3-weekly
N = 22
Weekly
N = 20
3-weekly
N = 26
Weekly
N = 26
3-weekly
N = 21
Weekly
N = 20
Age, median (range), yrs 52 (33-68) 50 (30-69) 48 (33-65) 45 (30-66) 54 (34-67) 53 (38-66) 52 (36-68) 54 (31-69)
ECOG performance status, n (%)         
   0 60 (87.0) 49 (74.2) 21 (95.5) 19 (95.0) 21 (80.8) 16 (61.5) 18 (85.7) 14 (70.0)
   1 7 (10.1) 15 (22.7) 1 (4.5) 1 (5.0) 4 (15.4) 9 (34.6) 2 (9.5) 5 (25.0)
   2 2 (2.9) 2 (3.1) - - 1 (3.8) 1 (3.8) 1 (4.8) 1 (5.0)
ER or PgR positive, n (%) 40 (58.0) 38 (57.6) 10 (45.5) 7 (31.8) 17 (65.4) 19 (73.1) 13 (61.9) 12 (60.0)
Previous epirubicin, n (%) - - - - - - 21 (100) 20 (100)
   neoadjuvant        3 (14.3) 1 (5.0)
   adjuvant        18 (85.7) 17 (85.0)
   both        - 2 (10.0)
Dose of previous epirubicin, median (range), mg/m² - - - - - - 422 (340-600) 485 (289-779)
At least one target lesion, n (%) 53 (76.8) 45 (68.2) 22 (100) 17 (77.3) 20 (76.9) 17 (65.4) 11 (52.4) 11 (55.0)
Dominant site of disease, n (%)         
   soft tissues (chest wall, breast and nodes) 31 (44.9) 22 (33.3) 22 (100) 20 (100) 6 (23.1) 1 (3.8) 3 (14.3) 1 (5.0)
   bone 6 (8.7) 4 (6.1) - - 5 (19.2) 2 (7.7) 1 (4.8) 2 (10.0)
   viscera (including pleura) 32 (46.4) 40 (60.6) - - 15 (57.7) 23 (88.5) 17 (81.0) 17 (85.0)